{"id":992,"date":"2021-04-30T12:40:53","date_gmt":"2021-04-30T12:40:53","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=992"},"modified":"2021-04-30T12:40:53","modified_gmt":"2021-04-30T12:40:53","slug":"20-apr-2021-nitazoxanide-was-associated-with-an-85-reduction-in-the-progression-to-severe-illness","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/20-apr-2021-nitazoxanide-was-associated-with-an-85-reduction-in-the-progression-to-severe-illness\/","title":{"rendered":"(20 Apr 2021) Nitazoxanide- was associated with an 85% reduction in the progression to severe illness"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.19.21255441v1<\/p>\n<p class=\"\">NCT04486313- Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction in the progression to severe COVID-19 (1\/184, [0.5%] nitazoxanide vs. 7\/195, [3.6%] placebo). In subjects at high-risk according to CDC criteria, 1\/112 (0.9%) of nitazoxanide-treated subjects and 7\/126 (5.6%) of placebo-treated subjects experienced progression to severe COVID-19. Treatment led to a 79% reduction in the rate of hospitalization (1\/184 [0.5%] nitazoxanide vs. 5\/195 [2.6%] placebo). The proportions positive for SARS-CoV-2 RNA and viral load at days 4 and 10 were not reduced. Nitazoxanide was safe and well tolerated. Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85% reduction in the progression to severe illness.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.19.21255441v1 NCT04486313- Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/20-apr-2021-nitazoxanide-was-associated-with-an-85-reduction-in-the-progression-to-severe-illness\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(20 Apr 2021) Nitazoxanide- was associated with an 85% reduction in the progression to severe illness&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,85],"tags":[86],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/992"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=992"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/992\/revisions"}],"predecessor-version":[{"id":993,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/992\/revisions\/993"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}